Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis

Nenhuma Miniatura disponível

Data

2019-07-01

Autores

Bezerra-Souza, Adriana
Fernandez-Garcia, Raquel
Rodrigues, Gabriela F.
Bolas-Fernandez, Francisco
Laurenti, Marcia Dalastra
Passero, Luiz Felipe [UNESP]
Lalatsa, Aikaterini
Serrano, Dolores R.

Título da Revista

ISSN da Revista

Título de Volume

Editor

Mdpi

Resumo

Leishmaniasis is a neglected tropical disease affecting more than 12 million people worldwide, which in its visceral clinical form (VL) is characterised by the accumulation of parasites in the liver and spleen, and can lead to death if not treated. Available treatments are not well tolerated due to severe adverse effects, need for parenteral administration and patient hospitalisation, and long duration of expensive treatments. These treatment realities justify the search for new effective drugs, repurposing existing licensed drugs towards safer and non-invasive cost-effective medicines for VL. In this work, we provide proof of concept studies of butenafine and butenafine self-nanoemulsifying drug delivery systems (B-SNEDDS) against Leishmania infantum. Liquid B-SNEDDS were optimised using design of experiments, and then were spray-dried onto porous colloidal silica carriers to produce solid-B-SNEDDS with enhanced flow properties and drug stability. Optimal liquid B-SNEDDS consisted of Butenafine:Capryol 90:Peceol:Labrasol (3:49.5:24.2:23.3 w/w), which were then sprayed-dried with Aerosil 200 with a final 1:2 (Aerosil:liquid B-SNEDDS w/w) ratio. Spray-dried particles exhibited near-maximal drug loading, while maintaining excellent powder flow properties (angle of repose <10 degrees) and sustained release in acidic gastrointestinal media. Solid-B-SNEDDS demonstrated greater selectivity index against promastigotes and L. infantum-infected amastigotes than butenafine alone. Developed oral solid nanomedicines enable the non-invasive and safe administration of butenafine as a cost-effective and readily scalable repurposed medicine for VL.

Descrição

Palavras-chave

butenafine, SNEDDS, solid SNEDDS, spray drying, leishmaniasis, design of experiments

Como citar

Pharmaceutics. Basel: Mdpi, v. 11, n. 7, 14 p., 2019.